SEC Form 4 · accession 0001213900-18-015513
DelMar Pharmaceuticals, Inc. · DMPI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Joseph Toth Jr.
Director
Period of report
Nov 8, 2018
Accepted (ET)
Nov 13, 2018 · 4:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001498382
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options (Right to Buy)F1 | $0.6099 | Nov 8, 2018 | A | 40,000 | A | — | Nov 8, 2028 | Common Stock | 40,000 | 40,000 | D |
Explanation of responses
- F1The shares subject to the option vest in twelve (12) equal monthly installments beginning on December 8, 2018.